ASX penny stock breaking out of consolidation
Pacific Edge has focused on securing Medicare coverage for Cxbladder though navigating short term operational challenges. Their latest update shows progress on both regulatory and clinical fronts.
Pacific Edge Limited (ASX: PEB)
reported its Q3 FY26 update highlighting regulatory progress and operational performance. The company is preparing for Novitas’ Contractor Advisory Committee meeting on 20 February, an important step before a potential new or revised Local Coverage Determination (LCD). This process is central to restoring long term Medicare reimbursement for Cxbladder.
A major positive development is the acceptance of Kaiser Permanente’s real world evidence study on Cxbladder Triage in Urology Practice. The study, previously previewed at the American Urological Association meeting, strengthens the clinical case and may support discussions at the upcoming CAC meeting. Also, Avalon Healthcare Systems has endorsed Cxbladder Triage as meeting coverage criteria, adding further third-party validation.
On reimbursement arguments, PEB has secured its first Medicare appeal hearing date for denied Cxbladder Triage claims, scheduled shortly after the CAC meeting. This marks progress in challenging coverage changes under the Genetic Testing for Oncology LCD.
Total laboratory throughput declined 13.4% to 5,446 tests in Q3. US volumes dropped 19.5%, reflecting reimbursement uncertainty and seasonal slowdown and APAC volumes increased 9.7% driven by commercial demand. Despite short-term pressure, PEB believes it is strategically positioned for a more stable Medicare framework in 2026.
(Source: Company Report)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
